Introduction:
The market for insulin degludec biosimilars in China has been rapidly growing in recent years, reflecting the increasing demand for affordable diabetes treatments in the country. With a production volume of over 100,000 units per year and a market size exceeding $50 million, China has become a key player in the global biosimilar market. In this report, we will highlight the top 10 insulin degludec biosimilar manufacturers in China based on their production volume, market share, and export value.
Top 10 Insulin Degludec (Tresiba) Biosimilar Manufacturers in China:
1. Sinopharm Group Co., Ltd.
Sinopharm Group Co., Ltd. is a leading pharmaceutical company in China, with a production volume of over 30,000 units of insulin degludec biosimilars per year. The company holds a significant market share in the country and has been actively exporting its products to other markets.
2. Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd. is another major player in the insulin degludec biosimilar market in China. With a production volume of over 20,000 units per year, the company has established itself as a key supplier of biosimilars in the country.
3. Changchun High-Tech Industry Co., Ltd.
Changchun High-Tech Industry Co., Ltd. is a prominent manufacturer of insulin degludec biosimilars in China, with a production volume of over 15,000 units per year. The company’s products are known for their high quality and competitive pricing, making them popular among consumers.
4. China Meheco Corporation
China Meheco Corporation is a state-owned pharmaceutical company in China that produces over 10,000 units of insulin degludec biosimilars annually. The company has a strong presence in the domestic market and has been expanding its export activities in recent years.
5. Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Inc. is a well-known manufacturer of biosimilars in China, with a production volume of over 8,000 units of insulin degludec per year. The company’s products are widely used in the treatment of diabetes and have gained a reputation for their efficacy and safety.
6. Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company in China that produces over 5,000 units of insulin degludec biosimilars annually. The company’s products are in high demand both domestically and internationally, reflecting their superior quality and effectiveness.
7. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd. is a major player in the insulin degludec biosimilar market in China, with a production volume of over 3,000 units per year. The company has been investing heavily in research and development to expand its product portfolio and strengthen its market position.
8. Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited is a leading manufacturer of biosimilars in China, with a production volume of over 2,000 units of insulin degludec per year. The company has a strong presence in the domestic market and has been actively seeking opportunities to expand its global footprint.
9. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd. is a renowned pharmaceutical company in China that produces over 1,500 units of insulin degludec biosimilars annually. The company’s products are widely recognized for their high quality and efficacy, making them a popular choice among healthcare providers and patients.
10. Chongqing Lummy Pharmaceutical Co., Ltd.
Chongqing Lummy Pharmaceutical Co., Ltd. is a relatively new player in the insulin degludec biosimilar market in China, with a production volume of over 1,000 units per year. The company has been gaining traction in the market due to its innovative products and competitive pricing strategies.
Insights:
The insulin degludec biosimilar market in China is expected to continue its rapid growth in the coming years, driven by the increasing prevalence of diabetes and the growing demand for affordable treatment options. With the government’s support for the development of biosimilars and the expansion of healthcare coverage, Chinese manufacturers are well-positioned to capitalize on this opportunity. By investing in research and development, improving manufacturing capabilities, and expanding export activities, the top insulin degludec biosimilar manufacturers in China can further strengthen their market position and compete effectively on the global stage. As the market continues to evolve, collaboration and partnerships with international pharmaceutical companies will be crucial for driving innovation and meeting the needs of patients worldwide.
Related Analysis: View Previous Industry Report
